Catumaxomab
EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)
Neovii Biotechmonoclonal_antibodyPhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
25 Active assets in the EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib Shandong Cancer Hospital and Institute | Phase 3 | BB |
Pembrolizumab Sheba Medical Center | Phase 2 | B |
Enadenotucirev Akamis Bio | Phase 1/2 | B |
Linifanib Abbott | Phase 3 | B |
Olaparib Xiaoxiang Chen | Phase 2 | CCC |
View all 36 →
Same molecule, other indications
Catumaxomab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →